Geographic disparity in the distribution of cancer clinical trials in the United States and the associated factors
Studies of new cancer treatments are located very unevenly in the United States with less than half of the country having any phase 1-3 cancer study between 2008 and 2022. Areas that are rural, poor, with less educated people, and fewer cancer doctors are less likely to have these studies. This may...
Saved in:
| Published in: | Journal of managed care & specialty pharmacy Vol. 30; no. 4; pp. 376 - 385 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Academy of Managed Care Pharmacy
01-04-2024
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Studies of new cancer treatments are located very unevenly in the United States with less than half of the country having any phase 1-3 cancer study between 2008 and 2022. Areas that are rural, poor, with less educated people, and fewer cancer doctors are less likely to have these studies. This may be problematic for patients who live in these areas to join studies of potentially life-saving cancer medicines.
Lack of local availability of cancer trials in disadvantaged areas limits the representativeness of trial population and generalizability of trial results and may later hinder the adoption of new cancer treatments in disadvantaged populations, leading to disparity in health outcomes. Lack of representation of underserved populations in clinical trials creates uncertainty in treatment efficacy in those patients, posing a challenge to value-based formulary decisions. |
|---|---|
| ISSN: | 2376-0540 2376-1032 |
| DOI: | 10.18553/jmcp.2024.30.4.376 |